Last updated: February 27, 2026
What Does NDC 69367-0251 Represent?
NDC 69367-0251 refers to Dyrene (mupirocin ointment). It is used primarily in the treatment of bacterial skin infections, including impetigo and secondary skin infections caused by susceptible strains of bacteria.
Market Size and Penetration
Current Market Overview
- Indications: Mupirocin ointment is primarily prescribed for uncomplicated skin infections. Its usage extends to nasal carriers for Staphylococcus aureus, including MRSA.
- Market Players: Major competitors include Bausch Health (Bausch + Lomb), Sandoz, and other generic manufacturers.
- Distribution channels: Pharmacy chains, hospitals, and outpatient clinics.
Market Penetration Drivers
- Antimicrobial resistance: Increasing MRSA prevalence favors mupirocin usage.
- Hospital pharmacy protocols: Often a first-line agent, especially for nasal decolonization.
- Prescribing trends: Growing outpatient use due to bacterial skin infections.
Estimated Market Size
- As of 2022, the US sales of mupirocin formulations amount to roughly $150 million annually, with proprietary formulations like Bactroban (mupirocin) accounting for approximately 80% of this share.
- The expansion in resistant strains and decolonization protocols sustains a compound annual growth rate (CAGR) of approximately 4-6% over the next five years.
Patent and Regulatory Status
- Patent status: Original patents expired around 2010. Subsequent patents protecting formulations or delivery mechanisms have expired or are close to expiry.
- Regulatory status: Approved by FDA for topical application in bacterial skin infections and for nasal decolonization.
Price Projections
Current Pricing Landscape
- Brand-name (Bactroban): Around $4.50 per gram at retail pharmacies.
- Generic mupirocin ointments: Typically priced between $2.00 and $2.50 per gram.
- Pack sizes: 15g and 30g tubes are common.
Future Price Trends
| Year |
Price per gram |
Explanation |
| 2023 |
$2.50 - $4.50 |
Market stability with brand premium persists. |
| 2025 |
$2.20 - $4.20 |
Entry of additional generics pressures prices downward. |
| 2027 |
$2.00 - $4.00 |
Increased generic market penetration potentially lowers prices further. |
Key Factors Impacting Pricing
- Generic competition: Market saturation with multiple generics tends to depress prices.
- Supply chain costs: Manufacturing and raw material prices influence final costs.
- Rebates and negotiated prices: PBMs and hospital systems negotiate discounts affecting retail prices.
- Regulatory changes: New formulations or delivery mechanisms could influence pricing structures.
Competitive Landscape and Innovation Potential
- Emerging formulations: Liposomal mupirocin prototypes aim to improve tissue penetration and reduce dosing frequency.
- Biosimilars: Currently not in development due to the nature of topical antibiotics, but potential future entrants could influence market pricing.
Pricing Outlook Summary
- The market will continue to see slight price erosion for generic mupirocin products.
- Brand-name products may retain a premium, though with increased generic competition, the gap narrows.
- The overall market value is expected to grow at approximately 4-6% CAGR through 2027, driven by antimicrobial resistance and nasal decolonization protocols.
Key Takeaways
- NDC 69367-0251 correlates to mupirocin ointment with stable demand driven by resistance patterns.
- The market is mature, with significant generic competition, leading to price compression.
- Prices are projected to decline slightly over the next five years, aligned with increased generic formulations.
- Sales growth will primarily result from increased use in nasal decolonization and resistant skin infections.
- Innovation is limited, though new delivery mechanisms could temporarily influence pricing strategies.
FAQs
1. What are the major competitors to mupirocin ointment?
Bausch Health's Bactroban is the leading proprietary product. Several generics manufactured by companies such as Sandoz, Mylan, and Perrigo compete on price.
2. How does antimicrobial resistance influence the market?
Rising resistance to other antibiotics positions mupirocin as a first-line agent, supporting sustained or increased demand.
3. What is the typical expiration timeline for mupirocin patents?
Original patents expired around 2010. No recent patents or exclusivities are in place, facilitating generic entry.
4. How are price negotiations affecting mupirocin markets?
Negotiations via PBMs and hospital purchasing groups primarily lower effective prices, although retail prices remain higher for brand-name versions.
5. Are there new formulations of mupirocin in development?
Yes. Liposomal and other novel delivery systems are under research but have yet to reach commercial availability.
References
[1] IQVIA. (2022). US Hospital & Retail Pharmacy Antibiotics Market Sales Data.
[2] U.S. Food and Drug Administration (FDA). (2022). Drug Approval and Patent Deadlines for Mupirocin.
[3] MarketWatch. (2022). Mupirocin Market Size and Forecasts.
[4] Sandoz. (2020). Mupirocin Drug Monograph.
[5] Bausch Health. (2022). Bactroban Product Information.
